Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
Contact us
Alterome Therapeutics
13480 Evening Creek Drive North
Suite 450
San Diego, CA 92128
General information
info@alterome.com
Clinical trials
clinical.trials@alterome.com
Biotech Fierce 15 honoree 2025 icon BioSpace NEXT GEN class of 2024 icon
Privacy Policy Terms of Use
© 2026 Alterome Therapeutics.
All rights reserved.